NASDAQ:AEZS Aeterna Zentaris (AEZS) Stock Price, News & Analysis $3.75 +0.30 (+8.70%) As of 05/1/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsTrendsBuy This Stock About Aeterna Zentaris Stock (NASDAQ:AEZS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aeterna Zentaris alerts:Sign Up Key Stats Today's Range$3.50▼$3.7550-Day Range$2.43▼$4.3552-Week Range$3.96▼$12.00Volume2,611 shsAverage Volume7,305 shsMarket Capitalization$6.72 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.Read More… Receive AEZS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aeterna Zentaris and its competitors with MarketBeat's FREE daily newsletter. Email Address AEZS Stock News HeadlinesStockNews.com Initiates Coverage on Aeterna Zentaris (NASDAQ:AEZS)April 27, 2025 | americanbankingnews.comCSCI:CA COSCIENS Biopharma Inc.September 18, 2024 | seekingalpha.comBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly positioning itself to overthrow the entire banking system.May 2, 2025 | Crypto 101 Media (Ad)Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc.August 6, 2024 | globenewswire.comChimerix Inc (CXF.BE)July 19, 2024 | finance.yahoo.comAeterna Zentaris Announces Results of Virtual 2024 Meeting of ShareholdersJuly 16, 2024 | globenewswire.comAeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone DeficiencyJune 13, 2024 | globenewswire.comShareholder Alert: Ademi LLP investigates whether Aeterna Zentaris Inc.'s transaction with Ceapro was Fair to ShareholdersJune 7, 2024 | prnewswire.comSee More Headlines AEZS Stock Analysis - Frequently Asked Questions How have AEZS shares performed this year? Aeterna Zentaris' stock was trading at $2.77 at the beginning of 2025. Since then, AEZS shares have increased by 35.4% and is now trading at $3.75. View the best growth stocks for 2025 here. How were Aeterna Zentaris' earnings last quarter? Aeterna Zentaris Inc. (NASDAQ:AEZS) posted its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($1.00) earnings per share for the quarter, beating the consensus estimate of ($2.00) by $1.00. The biopharmaceutical company had revenue of $0.60 million for the quarter, compared to analysts' expectations of $0.60 million. Aeterna Zentaris had a negative net margin of 760.32% and a negative trailing twelve-month return on equity of 83.45%. When did Aeterna Zentaris' stock split? Aeterna Zentaris shares reverse split on Friday, May 3rd 2024. The 1-4 reverse split was announced on Friday, May 3rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. How do I buy shares of Aeterna Zentaris? Shares of AEZS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aeterna Zentaris own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aeterna Zentaris investors own include Tonix Pharmaceuticals (TNXP), Bausch Health Companies (BHC), Ford Motor (F), DarioHealth (DRIO), Acasti Pharma (ACST), Onconova Therapeutics (ONTX) and Meta Platforms (META). Company Calendar Last Earnings11/04/2021Today5/02/2025Next Earnings (Estimated)5/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AEZS CIK1113423 Webwww.zentaris.com Phone(418) 652-8525Fax418-948-9191Employees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($14.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,550,000.00 Net Margins-760.32% Pretax Margin-760.28% Return on Equity-83.45% Return on Assets-45.76% Debt Debt-to-Equity RatioN/A Current Ratio5.94 Quick Ratio5.93 Sales & Book Value Annual Sales$2.37 million Price / Sales2.83 Cash FlowN/A Price / Cash FlowN/A Book Value$14.99 per share Price / Book0.25Miscellaneous Outstanding Shares1,793,000Free Float1,791,000Market Cap$6.72 million OptionableNo Data Beta1.55 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:AEZS) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aeterna Zentaris Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aeterna Zentaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.